These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 23208833)

  • 1. Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation.
    Eyler RF; Heung M; Pleva M; Sowinski KM; Park PK; Napolitano LM; Mueller BA
    Pharmacotherapy; 2012 Dec; 32(12):1061-9. PubMed ID: 23208833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oseltamivir pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation support.
    Mulla H; Peek GJ; Harvey C; Westrope C; Kidy Z; Ramaiah R
    Anaesth Intensive Care; 2013 Jan; 41(1):66-73. PubMed ID: 23362894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of extracorporeal membrane oxygenation and continuous venovenous hemodiafiltration on the pharmacokinetics of oseltamivir carboxylate in critically ill patients with pandemic (H1N1) influenza.
    Lemaitre F; Luyt CE; Roullet-Renoleau F; Nieszkowska A; Zahr N; Corvol E; Fernandez C; Antignac M; Farinotti R; Combes A
    Ther Drug Monit; 2012 Apr; 34(2):171-5. PubMed ID: 22354159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics of oseltamivir and oseltamivir carboxylate in a critically ill pediatric patient receiving extracorporeal membrane oxygenation and continuous venovenous hemodialysis.
    Eyler RF; Klein KC; Mueller BA
    J Pediatr Pharmacol Ther; 2012 Apr; 17(2):173-6. PubMed ID: 23118670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v.
    Petersen E; Keld DB; Ellermann-Eriksen S; Gubbels S; Ilkjær S; Jensen-Fangel S; Lindskov C
    Scand J Infect Dis; 2011 Jul; 43(6-7):495-503. PubMed ID: 21309638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extracorporeal membrane oxygenation for severe refractory respiratory failure secondary to 2009 H1N1 influenza A.
    Turner DA; Rehder KJ; Peterson-Carmichael SL; Ozment CP; Al-Hegelan MS; Williford WL; Peters MA; Noble PW; Cheifetz IM
    Respir Care; 2011 Jul; 56(7):941-6. PubMed ID: 21352668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma concentrations of oseltamivir and oseltamivir carboxylate in critically ill children on extracorporeal membrane oxygenation support.
    Wildschut ED; de Hoog M; Ahsman MJ; Tibboel D; Osterhaus AD; Fraaij PL
    PLoS One; 2010 Jun; 5(6):e10938. PubMed ID: 20532176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis.
    Robson R; Buttimore A; Lynn K; Brewster M; Ward P
    Nephrol Dial Transplant; 2006 Sep; 21(9):2556-62. PubMed ID: 16799169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of oseltamivir carboxylate in critically ill patients: each patient is unique.
    Kromdijk W; Sikma MA; van den Broek MP; Beijnen JH; Huitema AD; de Lange DW
    Intensive Care Med; 2013 May; 39(5):977-8. PubMed ID: 23443310
    [No Abstract]   [Full Text] [Related]  

  • 10. Peramivir pharmacokinetics in two critically ill adults with 2009 H1N1 influenza A concurrently receiving continuous renal replacement therapy.
    Bazan JA; Bauer KA; Hollister AS; Shidham G; Firstenberg MS; Reed EE; Mangino JE; Goff DA
    Pharmacotherapy; 2010 Oct; 30(10):1016-20. PubMed ID: 20874039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A.
    Rodríguez A; Díaz E; Martín-Loeches I; Sandiumenge A; Canadell L; Díaz JJ; Figueira JC; Marques A; Alvarez-Lerma F; Vallés J; Baladín B; García-López F; Suberviola B; Zaragoza R; Trefler S; Bonastre J; Blanquer J; Rello J;
    J Antimicrob Chemother; 2011 May; 66(5):1140-9. PubMed ID: 21385717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.
    Widmer N; Meylan P; Ivanyuk A; Aouri M; Decosterd LA; Buclin T
    Clin Pharmacokinet; 2010 Nov; 49(11):741-65. PubMed ID: 20923248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients.
    Isla A; Gascón AR; Maynar J; Arzuaga A; Toral D; Pedraz JL
    Clin Ther; 2005 May; 27(5):599-608. PubMed ID: 15978309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza.
    Ariano RE; Sitar DS; Zelenitsky SA; Zarychanski R; Pisipati A; Ahern S; Kanji S; Rello J; Kumar A
    CMAJ; 2010 Mar; 182(4):357-63. PubMed ID: 20159892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study.
    Philpott CD; Droege CA; Droege ME; Healy DP; Courter JD; Ernst NE; Harger NJ; Foertsch MJ; Winter JB; Carter KE; Van Fleet SL; Athota K; Mueller EW
    Pharmacotherapy; 2019 Nov; 39(11):1066-1076. PubMed ID: 31549737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detectability of vasopressin in continuous venovenous hemodialysis effluent of patients with vasodilatory shock treated with exogenous arginine vasopressin.
    Bauer SR; Culver DA; Abraham S; Lam SW; Fissell WH; Wiedemann HP; Reddy AJ
    Pharmacotherapy; 2011 Sep; 31(9):857-62. PubMed ID: 21923586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections.
    Lee N; Hui DS; Zuo Z; Ngai KL; Lui GC; Wo SK; Tam WW; Chan MC; Wong BC; Wong RY; Choi KW; Sin WW; Lee EL; Tomlinson B; Hayden FG; Chan PK
    Clin Infect Dis; 2013 Dec; 57(11):1511-9. PubMed ID: 24046309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and safety of intravenous oseltamivir in infants and children in open-label studies.
    Muñoz FM; Anderson EJ; Deville JG; Clinch B; Kamal MA
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):531-40. PubMed ID: 26042486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extracorporeal membrane oxygenation for critically ill patients with 2009 influenza A (H1N1)-related acute respiratory distress syndrome: preliminary experience from a single center.
    Hou X; Guo L; Zhan Q; Jia X; Mi Y; Li B; Sun B; Hao X; Li H
    Artif Organs; 2012 Sep; 36(9):780-6. PubMed ID: 22747918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza.
    Taylor WR; Thinh BN; Anh GT; Horby P; Wertheim H; Lindegardh N; de Jong MD; Stepniewska K; Hanh TT; Hien ND; Bien NM; Chau NQ; Fox A; Ngoc NM; Crusat M; Farrar JJ; White NJ; Ha NH; Lien TT; Trung NV; Day N; Binh NG
    PLoS One; 2008; 3(10):e3410. PubMed ID: 18923671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.